

**GCOM**  
2019



**3RD GLOBAL CONFERENCE  
ON MYOSITIS**

BERLIN, 27-30 MARCH 2019




PROGRAM HANDBOOK

GOLD SPONSOR:



# VENUES



1

**Conference Venue**  
European School of Management  
and Technology  
Schloßplatz 1  
10178 Berlin

2

**Scientific Get-Together**  
solar SKY-BAR  
Stresemannstraße 76  
10963 Berlin



## Table of Contents

Welcome .....	2
Committees / Organisation .....	3
Exhibitor .....	4
Poster Exhibition .....	6
General Information .....	9
Berlin - The LOC Top 10 .....	13
Program Summary .....	17
Program Wednesday, 27 March 2019 .....	21
Program Thursday, 28 March 2019 .....	25
Program Friday, 29 March 2019 .....	43
Program Saturday, 30 March 2019.....	61
Sponsors and Supporters .....	69

## Welcome to the 3rd Global Conference on Myositis (GCOM) in Berlin!

Dear Colleagues and Friends,

It is our great pleasure to welcome you in the vibrant city of Berlin for the 3rd edition of the Global Conference on Myositis. This year's conference is held in the European School of Management and Technology, right next to the newly re-built City Castle and the cultural heritage Museum Island.

You will surely enjoy the latest updates on clinical and scientific achievements in the field of myositis and neighbouring research fields. We are proud and delighted to welcome more than 360 participants this year from all over the world and we look forward to lively and fruitful discussions and intense networking on scientific and social levels.

We are also very pleased that this conference is constantly growing, developing and obviously attractive to many young clinicians and researchers and we are grateful to all our keynote speakers for their invaluable engagement to give state of the art overviews and their personal insights into specific research topics relevant to myology and immune mechanisms.


Having four exciting days ahead of us, we want to wish everyone a very inspiring and successful meeting as well as a wonderful and memorable time in Berlin.



Werner Stenzel (Chair)



Olivier Benveniste (Chair)



Ichizo Nishino (Chair)

and the Local Organising Committee

### Organising Committee

Stenzel, Werner (Chair) | Germany  
 Benveniste, Olivier (Chair) | France  
 Nishino, Ichizo (Chair) | Japan  
 Allenbach, Yves | France  
 Goebel, Hans-Hilmar | Germany  
 Hervier, Baptiste | France  
 Pehl, Debora | Germany  
 Preuße, Corinna | Germany


### Scientific Committee

Aggarwal, Rohit | USA  
 Allenbach, Yves | France  
 Amato, Antony | USA  
 Bader-Meunier, Brigitte | France  
 Benveniste, Olivier | France  
 Boyer, Olivier | France  
 Chinoy, Hector | UK  
 Christopher-Stine, Lisa | USA  
 de Blecker, Jan | Belgium  
 de Visser, Marianne | The Netherlands  
 Dimachkie, Mazen | USA  
 Feist, Eugen | Germany  
 Fujimoto, Manabu | Japan  
 Goebel, Hans-Hilmar | Germany  
 Greenberg, Steven | USA  
 Hervier, Baptiste | France  
 Kuwana, Matsaka | Japan  
 Lloyd, Thomas | USA  
 Lundberg, Ingrid | Sweden

### Professional Congress Organiser

Remember Management GmbH  
 Albrechtstraße 14 b  
 10117 Berlin  
 Tel.: +49 30 47372577  
 E-mail: [info@remember-management.de](mailto:info@remember-management.de)  
[www.remember-management.de](http://www.remember-management.de)

Mammen, Andrew | USA  
 Meyer, Alain | France  
 Miller, Fred | USA  
 Mozaffar, Tahseen | USA  
 Nagaraju, Kanneboyina | USA  
 Needham, Merrilee | Australia  
 Nishino, Ichizo | Japan  
 Pehl, Debora | Germany  
 Preuße, Corinna | Germany  
 Rider, Lisa | USA  
 Schmidt, Jens | Germany  
 Selva O' Callagan, Albert | Spain  
 Stenzel, Werner | Germany  
 Troyanov, Yves | Canada  
 Vencovský, Jiří | Czech Republic  
 Wang, Guochun | China  
 Wedderburn, Lucy | UK  
 Werth, Victoria | USA



1 **CSL Behring**  
Biotherapies for Life®

2 **MYOSITIS UK**

3 **THE MYOSITIS ASSOCIATION**

4 **EUROIMMUN**  
a Fortilizer company

5 **SANOFI GENZYME**

6 **ICON**

7 **DGM**  
Deutsche Gesellschaft  
für Muskelkranke e.V.  
Diagnosegruppe  
Myositis


8 **CureJM**  
FOUNDATION

9 **octapharma®**

11 **CORBUS**  
PHARMACEUTICALS

12 **BMC**

13 **MBL**



**EXHIBITION OPENING HOURS**


Wednesday, 27 March 2019	12:30 - 20:00
Thursday, 28 March 2019	08:30 - 20:00
Friday, 29 March 2019	08:30 - 17:30
Saturday, 30 March 2019	08:00 - 14:30


FOYER II

AUDITORIUM II

LECTURE HALL

COLONNADE





**Attendee List**

A list of attendees is to be found in the delegate bag. Please note that some attendees may be omitted from the list due to special request.

**Banks**

All major banks are located within walking distance to the conference venue.

**Car Rental**

Sixt rent a car: +49 18 06 252 525  
 Europcar: +49 40 520 187 654  
 Avis: +49 30 65 007 894

**Certificate of Attendance**

A Certificate of Attendance will be issued to the attendees upon returning a completed evaluation form to the Registration Counter.

**Child Care**

No official arrangements have been made for child care during the conference.

**Copy Shop**

Repro Central  
 Wallstraße 15, 10179 Berlin  
[www.repro-central.de](http://www.repro-central.de)  
 Tel.: 030 2029860  
 E-Mail: [kontakt@repro-central.de](mailto:kontakt@repro-central.de)  
 Operating Hours  
 Monday to Friday: 09:00 - 18:00  
 Saturday: 10:00 - 13:00

**Disability Assistance**

Please contact staff at the registration desk if you require assistance during the conference.

**Dress Code**

Conference Sessions: Casual  
 Welcome Reception: Casual  
 Scientific Get-Together: Casual

**Evaluation Form**

All attendees are kindly asked to complete the evaluation form provided in the delegate bag and to submit it at the Registration Counter. Please note that in order to receive a Certificate of Attendance the evaluation form must be submitted.



**CURE JM**

JM is a rare, life-threatening autoimmune disease that attacks children's muscles and skin. It can cause pain, disability, disfigurement, organ failure... even death.

As the leading organization dedicated to finding a cure, Cure JM funds genetic studies, explores new medications, and supports physicians and researchers.

Get involved in the solution. **15 Years Strong**

[CUREJM.ORG](http://CUREJM.ORG)

**Meals**

The registration fee includes lunch breaks, afternoon coffee breaks, and welcome reception.

Water and soft drinks will be available during the whole conference at service stations.

**Messages**

Messages can be delivered at the registration desk.

**Name Badge**

Your name badge is also your entry document. Please make sure to have it with you during the whole conference.

are very limited, which is why we advise you not to come to the venue by car. Here are the nearest parking garages in case you arrive by car:

Parkhaus Rathaus Passagen

Grunerstraße 5-7

10178 Berlin

*15 minutes walk to ESMT*

Q-Park Operncarrée

Französische Straße 39

10117 Berlin

*10 minutes walk to ESMT*

**Poster Set Up**

Posters are requested to be set up either on Wednesday, 27 March 2019, between 10:00 and 18:00 or Thursday, 28 March 2019, prior to the first coffee break at 10:00.

**Poster Pull Down**

Authors are responsible for the removal of their poster by no later than Saturday, 30 March 2019, 14:30. Any posters still in place at 14:30 on Saturday will be disposed.

**Poster Size**

DIN A0 (Width 84,1 cm / Height 118,9 cm)

**Public Transport**

The public transport companies of Berlin are called BVG (bus, tram and underground) and S-Bahn GmbH. They will take you quickly anywhere you need to go. Berlin is divided into three tariff zones. Tickets for tariff zones AB cover the urban area to the city boundary.

Tickets for zones ABC also cover Berlin's surrounding area and the city of Potsdam.

**Registration Counter**

The Registration Counter will be located in the ESMT-Foyer and will be open as follows:

Wednesday, 27 March 2019 09:00 - 18:30

Thursday, 28 March 2019 08:00 - 19:00

Friday, 29 March 2019 08:00 - 19:00

Saturday, 30 March 2019 08:00 - 14:00

**Smoking Policy**

Smoking is allowed only outside the buildings. No smoking at the conference venue!

**Media Check**

For oral presenters, the Media Check (Speakers Preview Area) is located in the first floor on the right side.

This room will be provided for all presenters and offers the opportunity to check-in presentations with the audio and visual aid provided. This area will be staffed and will be available for the duration of the conference. All speakers are required to visit the Media Check and provide their presentation on a USB device at least two hours prior to the commencement of their presentation.

**The Myositis Association (TMA)**

is the leading international organization committed to patient support and education, awareness, advocacy, and research funding for myositis diseases.



**TMA's Research Grant Program is now accepting applications**

Researchers are encouraged to submit proposals for pilot projects or fellowship support. Please join us on **April 9 at 12pm EST** for a webinar

**Position Your Grant Application for Success**

For more information: [www.myositis.org](http://www.myositis.org)



THE MYOSITIS ASSOCIATION



## TALES OF THE UNEXPECTED: DECIPHERING THE CLUES TO EARLIER DIAGNOSIS IN MYOSITIS VS METABOLIC MYOPATHY

**FRIDAY 29 MARCH 2019, 12:30–14:00**

Auditorium Maximum, European School of Management and Technology, Berlin

Satellite Symposium at GCOM 2019, 3<sup>rd</sup> Global Conference on Myositis





The Media Check will be staffed during the following times:

Wednesday, 27 March 2019	10:00 - 19:00
Thursday, 28 March 2019	08:00 - 17:30
Friday, 29 March 2019	08:00 - 19:00
Saturday, 30 March 2019	08:00 - 14:00

#### Useful Telephone Numbers

Ambulance/Fire brigade:	112
Police:	110
In case of poisoning:	+49 30 19240

#### Weather in Berlin

Berlin has a continental climate, with cold winters and often quite hot summers. In March you may find both rainy and sunny days, with temperatures between 5°C and 12°C.

#### W-LAN

There is a hot spot located at the conference venue called GCOM2019 (password: BERLIN!!).

## Immunoglobulin replacement and immunomodulation therapies...

...with more than three decades of experience

"I recovered the control of my life"

Jessica, 42

octapharma

## Welcome to Germany's capital city!

Berlin, the capital, is one of 16 states in Germany. With about 3.5 million people it is its largest city. Located in the beautiful region of Berlin-Brandenburg, this city has a remarkable history and was divided into East Berlin and West Berlin during the Cold War. Today, Berlin hosts three well reputed universities, one of the best philharmonic orchestras worldwide and three opera houses. A large diversity of museums and one of Europe's largest university hospitals, the Charité. Berlin is also known for being a very important center of scientific research, with prestigious institutes and research organisations, such as the Max-Planck-Institute, the 'Fraunhofer-Gesellschaft' and the 'Leibniz-Gemeinschaft'. Berlin attracts especially young and creative people from all over the world, offering a high quality of life, a fascinating cultural scene and interesting career opportunities.



**Berlin TV Tower:** Do you want to discover Berlin 360°? Then you are in just the right place at the TV Tower. From 203 and 207 metres height you can look out over the entire city with its large number of tourist attractions. *Alexanderplatz, 10178 Berlin / +49 30 242 33 33 / daily 09:00 - 24:00 / [www.berlinerfernsehturm.de](http://www.berlinerfernsehturm.de)*

**Brandenburg Gate & Memorial to the murdered Jews of Europe:** The Brandenburg Gate is one of Berlin's most important monuments – a landmark and symbol all in one with over two hundred years of history. Berlin's Holocaust Memorial, located in Mitte on a stretch of the former "death strip", where the Wall once stood near the Brandenburg Gate, is Berlin's stunning monument to the Holocaust, dedicated to the Jewish victims of the Nazi genocide of World War II. *Pariser Platz / Cora-Berliner-Straße 1, 10117 Berlin / +49 30 26 39 43 36 / accessible around the clock / [www.holocaust-mahnmal.de](http://www.holocaust-mahnmal.de)*





**The Potsdamer Platz:** The Potsdamer Platz quarter is one of the most exciting and multifaceted corners of the German capital. Up to 100,000 people come to this square every day to experience the unique blend of art, entertainment, shopping and cosmopolitan flair – and ultimately to feel a touch of history.

*Potsdamer Platz, 10785 Berlin / [www.potsdamerplatz.de/en](http://www.potsdamerplatz.de/en)*

**Tiergarten & Siegessäule:** The Tiergarten (animal garden) and former hunting ground is Berlin's best known park. Because of its centrality it is a favourite for locals and visitors, wonderful for a stroll, a breath of fresh air, a picnic, cycling or a jog or just kicking a ball around. The Siegessäule (victory column) located in the center of the Tiergarten has reinvented itself through the ages – from symbol of Prussian military victory in the 19th century to a favourite tourist spot today. *Straße des 17. Juni, 10557 Berlin / +49 30 391 29 61 / Mon-Fri 09:30 - 18:30, Sat-Sun 09:30 - 19:00 / [www.siegessaule.de](http://www.siegessaule.de)*



**Museum Island:** Located in the heart of the city the museum island is one of the places you should not miss to visit in Berlin. Since 1999 this architectural and cultural ensemble is considered part of the UNESCO world heritage. On the museum island you can visit five of Berlin's most interesting museums, such as Pergamon Museum, Bode-Museum, Neues Museum, Alte Nationalgalerie and Altes Museum.

*Bodestraße, 10178 Berlin / +49 30 20 90 55 77 / opened daily / [www.smb.museum](http://www.smb.museum)*



**German Reichstag, Parliament:** The Reichstag building was completed in 1894 following German national unity and the establishment of the German Reich in 1871. A visit to the Reichstag is a must. Visitor highlights include a lift ride to the top of the building to a large viewing terrace for the breathtaking views of Tiergarten, the dome and the mirror cylinder at the centre. *Platz der Republik, 10557 Berlin / +49 30 22 73 21 52 / daily 08:00 - 23:00 / [www.bundestag.de](http://www.bundestag.de)*

**Berlin Cathedral:** The Cathedral of Berlin is the largest church in the city. Beneath wonderful fresques you may also admire the impressive Sauer organ with its 7269 pipes and 113 registers. *Am Lustgarten, 10178 Berlin / +49 30-202 69-136 / Mon-Sat 09:00 - 19:00, Sun 12:00 - 19:00 / [www.berlinerdom.de](http://www.berlinerdom.de)*



**East Side Gallery:** It is the largest open-air gallery in the world with over one hundred original mural paintings. Galvanised by the extraordinary events which were changing the world, artists from all around the globe rushed to Berlin after the fall of the Wall, leaving a visual testimony of the joy and spirit of liberation which erupted at the time. *Mühlenstraße 3-100, 10243 Berlin / +49 30 251 71 59 / accessible around the clock / [www.eastsidegallery-berlin.de](http://www.eastsidegallery-berlin.de)*



**Potsdam:** Potsdam is the capital city of the German federal state of Brandenburg. It directly borders the German capital Berlin and is part of the Berlin/Brandenburg Metropolitan Region. The most popular attraction in Potsdam is Sanssouci Park, 2 km west of the city centre. In 1744 King Frederick the Great ordered the construction of a residence here, where he could live sans souci. The park hosts a botanical garden and many buildings. [www.potsdam.de](http://www.potsdam.de)

**The German Society of Muscular Diseases (DGM)** is the largest and oldest German self-help organization for people with neuromuscular diseases with over 8500 members.

Our request:

- promote research
- advise affected and relatives
- represent health policy interests
- realize self-determination and participation
- support health literacy and self-help



**DGM**

**Deutsche Gesellschaft  
für Muskelkranke e. V.**

**Diagnosegruppe  
Myositis**

**[www.dgm.org](http://www.dgm.org)**



**Berlin Underworlds (Berliner Unterwelten):** Here you have a broad look into the city's underground. The main focus, however, is civil defence in the Second World War, the effects of bomb war and modern archaeological finds of the twentieth century.


*Brunnenstr. 105, 13355 Berlin / +49 30 49 91 05 17*

*/ Mon-Fri 10:00 - 16:00 /*

*[www.berliner-unterwelten.de](http://www.berliner-unterwelten.de)*

A microscopic view of muscle tissue, showing numerous muscle fibers with visible nuclei and connective tissue. The fibers are arranged in a regular, repeating pattern, typical of skeletal muscle tissue. The color is a warm, golden-brown, suggesting a histological stain like hematoxylin and eosin (H&E).

# PROGRAM SUMMERY




**WEDNESDAY, 27 MARCH 2019**

10:00 - 12:30	<b>Pre-Congress Pathology Workshop</b>	Lecture Hall
12:30 - 14:00	<b>LUNCH</b>	Foyer I and II
14:00 - 15:00	<b>Welcome</b> O Benveniste, I Nishino and W Stenzel	Lecture Hall
	<b>General Lecture:</b> Recent developments in therapeutic approaches for neuromuscular diseases T Voit	
15:00 - 16:30	<b>I Sporadic Inclusion Body Myositis (sIBM)</b> Chairs: T Lloyd and J Zschüntzsch	Lecture Hall
16:30 - 17:15	<b>COFFEE BREAK</b>	Foyer I and II
17:15 - 18:30	<b>Ila Extramuscular (Neoplasia)</b> Chairs: Y Allenbach and M de Visser	Lecture Hall
18:30	<b>Welcome Reception</b>	Foyer I and II

**THURSDAY, 28 MARCH 2019**

08:30 - 10:00	<b>IIb Extramuscular (Lung)</b> Chairs: B Hervier and M Needham	Lecture Hall
10:00 - 11:15	<b>COFFEE BREAK and Exhibition</b>	Foyer I and II
	<b>Poster Session I: Parallel Sessions</b>	Colonnade and Foyer I
	 Dermatomyositis (P.001-P.024)	
	 Extramuscular Aspects in Myositis (P.025-P.040)	
	 Trials (P.041-P.044)	
11:15 - 12:45	<b>III Treatment and Trials</b> Chairs: B Feldman and O Landon-Cardinal	Lecture Hall
12:45 - 14:00	<b>LUNCH</b>	Foyer I and II
14:00 - 16:00	<b>Workshop for Young Physicians/Researchers</b> Chairs: O Benveniste, H Chinoy, L Christopher-Stine, M Fujimoto, A Mammen, I Nishino, L Rider and W Stenzel	Auditorium II
14:00 - 16:00	<b>Patient-Centered Workshop</b> Chairs: J Schmidt and S Schlüter	Lecture Hall
16:00 - 16:45	<b>SNACK BREAK and Exhibition</b>	Foyer I and II
	<b>Poster Session II: Parallel Sessions</b>	Colonnade
	 Juvenile Dermatomyositis (P.045-P.063)	
	 Immune-Mediated Necrotizing Myopathies (P.064-P.074)	
16:45 - 20:00	<b>Team Workshop jDM</b> Chairs: K Adelan and L Rider	Lecture Hall
16:45 - 18:45	<b>Speed-Funding</b> Chairs: Y Allenbach, H Chinoy, A Kubota, A Meyer, D Pehl, C Preuße and J Tanboon	Auditorium II



**FRIDAY, 29 MARCH 2019**

08:30 - 10:00	<b>IVa Juvenile Dermatomyositis (jDM)</b> Chairs: A Selva-O'Callagan and B Bader-Meunier	Lecture Hall
10:00 - 11:15	<b>COFFEE BREAK and Exhibition</b>	Foyer I and II
	<b>Poster Session III:</b>	Colonnade and Foyer I
	 Miscellaneous (P.075-P.114)	
11:15 - 12:30	<b>IVb Dermatomyositis (DM)</b> Chairs: M Fujimoto and V Werth	Lecture Hall
12:30 - 14:00	<b>LUNCH / Genzyme Industry Symposium</b>	Lecture Hall
	SPONSORED BY: 	
14:00 - 15:30	<b>V Immune-Mediated Necrotizing Myopathies (IMNM)</b> Chairs: I Lundberg and G Wang	Lecture Hall
15:30 - 16:30	<b>SNACK BREAK and Exhibition</b>	Foyer I and II
	<b>Poster Session IV: Parallel Sessions</b>	Colonnade and Foyer I
	 Sporadic Inclusion Body Myositis (P.115-P.131)	
	 Other Forms of Myositis (P.132-P.151)	
16:30 - 17:00	<b>IMACS Meeting</b> Chairs: F Miller and L Rider	Lecture Hall
17:00 - 17:30	<b>Establishing a World Myositis Society:</b> Where do we go from here? Chair: J Schmidt	Lecture Hall
18:30	<b>Scientific Get-Together</b>	solar SKY-BAR





**SATURDAY, 30 MARCH 2019**

08:30 - 09:20	<b>VI New Treatment Options</b> Chairs: S Greenberg and U Schneider	Lecture Hall
09:20 - 10:00	<b>VII Miscellaneous</b> Chairs: O Boyer and J Lamb	Lecture Hall
10:00 - 10:30	<b>COFFEE BREAK and Exhibition</b>	Foyer I and II
10:30 - 11:15	<b>VIII Hot Topics</b> Chairs: HH Goebel and J Vencovský	Lecture Hall
11:15 - 12:15	<b>IX Patients</b> Chair: M Dimachkie	Lecture Hall
12:15 - 13:15	<b>Prizes</b> T Lloyd and V Werth	Lecture Hall
	<b>General Discussion, Closing and Handover</b> O Benveniste, I Nishino and W Stenzel	
13:15 - 14:30	<b>LUNCH</b>	Foyer I and II




A detailed microscopic image of skeletal muscle tissue, stained with hematoxylin and eosin (H&E). The image shows numerous muscle fibers with distinct nuclei and striations, separated by connective tissue. The overall color palette is dominated by shades of pink, red, and orange.

# WEDNESDAY

27 MARCH 2019

WEDNESDAY

WEDNESDAY




**WEDNESDAY, 27 MARCH 2019**

10:00 - 12:30	<b>Pre-Congress Pathology Workshop</b> Make the diagnosis - difficult cases including morphology Chairs: A Amato (USA), A Mammen (USA) and I Nishino (Japan)	Lecture Hall
12:30 - 14:00	<b>LUNCH</b>	Foyer I and II
14:00 - 15:00	<b>Welcome</b> O Benveniste (France), I Nishino (Japan) and W Stenzel (Germany)	Lecture Hall
	<b>General Lecture</b> Recent developments in therapeutic approaches for neuromuscular diseases T Voit (UK)	
15:00 - 16:30	<b>I Sporadic Inclusion Body Myositis (sIBM)</b> Chairs: T Lloyd (USA) and J Zschüntzsch (Germany)	Lecture Hall
15:00 - 15:25	1: Muscle aging M Kjaer (Denmark)	
15:25 - 15:50	2: Pathogenic mechanisms connecting inherited and acquired inclusion body myopathy C Wehl (USA)	
15:50 - 16:30	3: Selected oral presentations	
	O.01 Xenograft model of sporadic inclusion body myositis K Britson (USA)	
	O.02 Targeting highly differentiated effector memory KLRG1+ cytotoxic T cells in inclusion body myositis S Greenberg (USA)	
	O.03 CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis G Dzangué-Tchoupou (France)	

16:30 - 17:15 **COFFEE BREAK**

Foyer I and II

17:15 - 18:30 **Ila Extramuscular (Neoplasia)**

Lecture Hall

Chairs: Y Allenbach (France) and M de Visser (The Netherlands)

17:15 - 17:40 1: Lessons learnt from immune checkpoint inhibitor cardiovascular toxicities

J Moslehi (USA)

17:40 - 18:30 2: Selected oral presentations

O.04 Overall and site-specific cancer risk before and after diagnosis of idiopathic inflammatory myopathies: Novel register data from 2002 to 2016 in Sweden

L Dani (Sweden)

O.05 Immunization of dermatomyositis-specific auto-antigen transcriptional intermediary factor (TIF1)- $\gamma$  induces myositis in mice

N Okiyama (Japan)

O.06 The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody positive dermatomyositis

A Oldroyd (UK)

O.07 Pruritogenic mediators in skin samples of patients with dermatomyositis

A Vincze (Hungary)

18:30 **Welcome Reception:** Berlin history in a nutshell

Foyer I and II

J Marberg (Germany)



---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---


---



# THURSDAY

28 MARCH 2019

THURSDAY



**THURSDAY, 28 MARCH 2019**

- 08:30 - 10:00 **IIb Extramuscular (Lung)** Lecture Hall  
Chairs: B Hervier (France) and M Needham (Australia)
- 08:30 - 08:55 1: How to evaluate clinical outcomes of myositis-associated interstitial lung disease  
M Kuwana (Japan)
- 08:55 - 09:20 2: Lungs as a trigger of autoimmunity: The role of environmental factors  
L Klareskog (Sweden)
- 09:20 - 10:00 3: Selected oral presentations
- O.08 High level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis  
Q Peng (China)
  - O.09 Anti-MDA5 antibody-associated dermatomyositis: Three subgroups with different outcomes  
S Toquet (France)
  - O.10 Risk stratification in patients with anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease treated initially with intensive combination regimen  
T Gono (Japan)





10:00 - 11:15 **COFFEE BREAK and Exhibition**

Foyer I and II

**Poster Session I (P.001-P.044)**

Colonnade and Foyer I

**Dermatomyositis (P.001-P.024)**

- P.001 Autoantibody to transcriptional intermediary factor-1 $\beta$  as myositis-specific antibody: clinical correlation with CADM or DM with mild myopathy  
Y. Hamaguchi; I. Ueda-Hayakawa; K. Takehara; M. Fujimoto
- P.002 Laboratory diagnostics of autoantibodies in autoimmune myopathies  
M. Mende; W. Meyer; T. Scheper
- P.003 Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies  
H. F. Espinosa-Ortega; M. Holmqvist; H. Storfors; T. Mimori; I. E. Lundberg; J. Rönnelid
- P.004 The RIG-I pathway is involved in lymphopenia in patients with dermatomyositis  
L. Zhang; Q. Xia; W. Li; Q. Peng; X. Lu, G. Wang
- P.005 Clinical symptoms indicative of a paraneoplastic etiology in adult dermatomyositis patients: A retrospective case-control study  
G. Nagy; S. Husz; L. Kemény; L. Kovács; Z. Bata-Csörgő
- P.006 Pronounced focal muscle pathology in a patient with Anti-NXP2 autoantibody associated severe myositis  
L. Rager; M. Meyer; M. Yenigün; C. Preusse; H. Krämer-Best; S. Wolff; W. Stenzel; A. Schänzer
- P.007 Short-term changes after treatments in needle electromyography among patients with polymyositis and dermatomyositis: A retrospective study  
H. Kawasumi; Y. Katsumata; E. Ito; Y. Kawaguchi
- P.008 Clinical characteristics of patients with clinically amyopathic dermatomyositis positive for anti-TIF1r antibody  
Y. Yamaguchi; M. Kanaoka; A. Akita; Y. Ototake; T. Watanabe; N. Ikeda; M. Aihara
- P.009 Anti-calreticulin antibody – A Novel Autoantibody in Patients with Idiopathic Inflammatory Myopathies and Its Association with Malignancy  
H. Chen; Y.-P. Ge; G.-C. Wang; H.-B. Yang; Q.-L. Peng; Y.-M. Zhang; X. Lu
- P.010 Specific autoantibodies and clinical phenotypes correlate with the aberrant expression of immune-related microRNAs in Dermatomyositis  
L. Ye; X. Shu; G. Wang
- P.011 Increased serum Galectin-9 (Gal-9) in patients with idiopathic inflammatory myopathies  
L. Liang; Q. Peng; H. Chen; Y. Zhang; X. Lu; G. Wang
- P.012 Myogenesis impairment in Dermatomyositis  
L. Gallay; N. Streichenberger; G. Mouchiroud; B. Chazaud
- P.013 The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality and cancer in adult dermatomyositis  
A. Aussy; M. Fréret; L. Gallay; L. Drouot; F. Jouen; Y. Allenbach; O. Benveniste; N. Cordel; O. Boyer



- P.014 Association of IL-17RC rs708567 polymorphism with dermatomyositis: a pilot study  
J. Pozharashka; L. Dourmishev; Z. Kamenarska; M. Hristova; G. Dzhebir; S. Nikolova; A. Vinkov; R. Kaneva; L. Miteva
- P.015 Dermatomyositis associated with antibodies to small ubiquitin like modifier activating enzyme: a retrospective series of 41 cases  
M. Vautier; P. Duffau; O. Chosidow; A. Berezne; N. Cordel; J. Schmidt; M. Jachiet; J. Graveleau; N. Champtiaux; P. Guillaume-Jugnot; B. Hervier; J. Victor; A. Rigolet; O. Landon-Cardinal; O. Benveniste; Y. Allenbach
- P.016 Dermatomyositis with anti-MDA5 auto-antibodies: is there a seasonal pattern of disease onset?  
K. Mariampillai; S. Toquet; Y. Uzunhan; G. Leroux; L. Gallay; A. Meyer; H. Nunes; B. Granger; O. Benveniste; Y. Allenbach
- P.017 Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective  
L. Christopher-Stine; W. Nelson; W. Kelly; L. Kobert; B. Opong-Owusu; M. Reed
- P.018 Murin model of anti-TIF1gamma dermatomyositis: preliminary results  
A. Aussy; M. Chilles; L. Drouot; F. Jouen; C. Arnoult; O. Benveniste; O. Boyer
- P.019 Novel Nailfold Video Capillaroscopy Parameters for Monitoring Juvenile and Adult Dermatomyositis  
N. Arnett; H. Prakash; A. Gorbach; F. Miller; L. Rider; A. Schiffenbauer
- P.020 Distinct clinical profiles of Chinese and Swedish idiopathic inflammatory myopathy patients with anti-melanoma differentiation associated gene 5 (MDA5) antibody  
H. So; I. Lundberg; M. Dastmalchi; V. Leclair; T. Lam; R. Ho; V. Wong
- P.021 The clinical significance of progranulin in DM patients  
S.-S. Li; Y. Zhang; X. Lu; G. Wang
- P.022 Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for adult idiopathic inflammatory myopathies in a Hong Kong cohort  
H. So; R. Ho; T. Lam; V. Wong
- P.023 Anti-NXP2 Dermatomyositis : a severe muscle and skin disease  
C. Rasmussen; L. Gallay; A. Meyer; D. Larivière; S. Leonard-Louis; P. Guillaume-Jugnot; M. Vauthier; K. Mariampillai; O. Benveniste; Y. Allenbach
- P.024 NVC (nailfold videocapillaroscopy) in MDA5 positive patients with and without skin ulcers  
F. Berianu
- Extramuscular Aspects in Myositis (P.025-P.040)**
- P.025 Infections are leading cause of in-hospital mortality in Indian patients with inflammatory myositis  
H. Muhammed; L. Gupta; A. Arvind Zanwar; D. P. Misra; A. Lawrence; V. Agarwal; A. Aggarwal; R. Misra
- P.026 The Predictive Risk Factors for Opportunistic Infection during treatment for Polymyositis/dermatomyositis  
Y. Sugiyama; R. Yoshimi; M. Takeno; Y. Kirino; S. Ohno; H. Nakajima



- P.027 Pneumocystis jirovecii pneumonia (PCP) in Patients with Idiopathic inflammatory myopathy  
Y.-P. Ge; X. Lu; G. Wang; S.-Z. Li
- P.028 Alterations of Body Composition in Myositis Patients Are Associated with Disease Activity, Duration and Muscle Involvement  
S. Oreska; M. Spiritovic; H. Storkanova; B. Hermankova; K. Pavelka; L. Senolt; H. Mann; J. Vencovsky; M. Tomcik
- P.029 Prevalent Vertebral Fractures incur high risk of future fractures in inflammatory myositis  
S. Ganguly; A. Lawrence; R. Misra; L. Gupta; S. Sahoo
- P.030 Poor muscle endurance of swallowing muscles in myositis patients with dysphagia  
A. Azola; T. Chung; L. Christopher-Stein
- P.031 miR-1 Is a Novel Biomarker for Polymyositis/ dermatomyositis-associated Interstitial Lung Disease  
Y. Sugiyama; R. Yoshimi; M. Takeno; Y. Kirino; S. Ohno; H. Nakajima
- P.032 Clinical significance of radiological pattern of HRCT and macrophage activation for polymyositis and dermatomyositis patients with different MSAs  
Y. Zuo; L. Ye; M. Liu; F. Chen; X. Lu; G. Wang; X. Shu
- P.033 Reliability of PET/TC cancer screening in a large cohort of patients diagnosed with idiopathic inflammatory myopathy  
A. Gil-Vila; E. Trallero-Araguás; M. Alvarado-Cardenas; I. Pinal-Fernandez; X. Martínez-Gómez; J. Castells-Conesa; A. Selva-O'Callaghan
- P.034 Tumour Infiltrating Lymphocytes quantification in Cancer-Associated Dermatomyositis  
J. Ros; J. Lostes; P. Nuciforo; C. Viaplana; J. Milisenda; E. Trallero-Araguás; I. Pinal-Fernandez; A. Gil-Vila; J. M. Grau-Junyent; R. Dienstmann; A. Selva-O'Callaghan
- P.035 Traditional and disease-related risk factors for arterial and venous thrombotic events (TE) in idiopathic inflammatory myopathies (IIM)  
A. Notarnicola; S. Barsotti; L. Näsman; Q. Tang; M. Holmqvist; I. E. Lundberg; A. Antovic
- P.036 The potassium channel KCNK2 is a regulator of immune cell trafficking and inflammatory responses in idiopathic inflammatory myopathies  
T. Müntefering
- P.037 Infection in patients with Idiopathic Inflammatory Myopathies  
Y.-P. Ge; G.-C. Wang; X. Lu; S.-Z. Li; L.-R. He
- P.038 Frequency, Risk factor, Outcome and Prognostic factor in Calcinosis of Adult Idiopathic Inflammatory Myopathy: Single Center Cohort Study  
W. Jiang; K. Yang; S. Li; X. Tian; L. Zhang; X. Lu; G. Wang
- P.039 A single center experience using a clustering approach to identify clinico-serological phenotypes in Idiopathic Inflammatory Myopathies  
V. Leclair; A. S. Galindo Feria; I. E. Lundberg; L. Padyukov; L. M. Diaz-Gallo
- P.040 Creatinine- and cystatin C-estimated glomerular filtration rate for estimating renal function during inclusion body myositis  
O. Mangin; J. P. Bertocchio; Y. Allenbach; G. Maruani; P. Houillier; O. Benveniste

**Trials (P.041-P.044)**

- P.041** Design of Phase 3 Study of Lenabasum for the Treatment of Dermatomyositis  
V. P. Werth; C. V. Oddis; I. E. Lundberg; D. Fiorentino; C. Cornwall; N. Dgetluck; S. Constantine; B. White
- P.042** Patient reported outcome core set for adult idiopathic inflammatory myopathies  
C. Mecoli; M. Regardt; J. K. Park; I. de Groot; C. Sarver; M. Needham; M. de Visser; C. Bingham III; I. Lundberg; Y. Wook Song; H. Alexanderson; L. Christopher-Stine
- P.043** Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis  
H. Kim; S. Dill; M. O'Brien; A. Brundidge; L. G. Rider; R. A. Colbert
- P.044** Intravenous iMMunoglobulins as Early treatment in newly DIAGnosed idiopathic inflammaTory myopathies (IMMEDIATE): a phase-2 open-label pilot study.  
J. Lim; M. Jaring; A. Amin; Y. Pinto; N. Planken; M. Boekholdt; A. van der Kooi
- 11:15 - 12:45 **III Treatment and Trials** Lecture Hall  
 Chairs: B Feldman (Canada) and O Landon-Cardinal (Canada)
- 11:15 - 11:40 1: Bayesian statistics for rare diseases (from registries to clinical trials)  
 L Biard (France)
- 11:40 - 12:05 2: Trial readiness in rare diseases  
 V Straub (UK)

- 12:05 - 12:45 3: Selected oral presentations
- O.11 Quantitative high throughput screening of small molecule libraries to inhibit interferon beta-stimulated major histocompatibility complex class I in myositis muscle  
 T Kinder (USA)
- O.12 Study of Tofacitinib in refractory dermatomyositis  
 J Paik (USA)
- O.13 A one-year study investigating the effect of specialised and intensive ADL training in patients with idiopathic inflammatory myopathies - preliminary results  
 M Špiritović (Czech Republic)

12:45 - 14:00 **LUNCH** Foyer I and II

14:00 - 16:00 **Workshop for Young Physicians/Researchers:** Auditorium II  
 Clinics & Research: Specificities in different countries. How to improve international collaborations?  
 Chairs: O Benveniste (France), H Chinoy (UK), L Christopher-Stine (USA), M Fujimoto (Japan), A Mammen (USA), I Nishino (Japan), L Rider (USA) and W Stenzel (Germany)

14:00 - 16:00 **Patient-Centered Workshop** Lecture Hall  
 Chairs: J Schmidt (Germany) and S Schlüter (Germany)

- 1: How to assess patient reported outcome (PRO)  
 PRO in IIM: Where do we stand  
 C Mecoli (USA)  
 E-technologies in IIM  
 O Landon-Cardinal (Canada)  
 Devices in IIM  
 R Aggarwal (USA)

2: 1h Q&A with patients



- 16:00 - 16:45 **SNACK BREAK and Exhibition** Foyer I and II
- Poster Session II (P.045-P.074)** Colonnade
- Juvenile Dermatomyositis (P.045-P.063)**
- P.045 Preliminary prospective validation of the juvenile dermatomyositis activity index (jDMAI)  
S. Rosina; G. C. Varnier; A. Consolaro; P. van Dijkhuizen; K. Nistala; N. Ruperto; A. Pistorio; C. Pilkington; A. Ravelli
  - P.046 Nodular Regenerative Hyperplasia of the Liver in Juvenile Dermatomyositis  
R. Volochayev; D. E. Kleiner; P. Gowda; A. Vittal; T. Heller; L. G. Rider
  - P.047 Preliminary Validation of Rectus Femoris Muscle Ultrasound in Juvenile Dermatomyositis  
E. McBride; G. Mamyrova; M. Harris-Love; A. Premkumar; D. Koziol; J. Yao; L. Yao; J. Shrader; R. Curiel; L. Rider
  - P.048 Circulating microparticles as potential markers of disease progression and vascular dysfunction in Juvenile Dermatomyositis  
C. Papadopoulou; Y. Hong; P. Krol; Y. Ioannou; C. Pilkington; M. Charakida; L. R. Wedderburn; P. Brogan; D. Eleftheriou
  - P.049 Efficacy of Adrenocorticotrophic Hormone Gel (Acthar) in Refractory Juvenile Dermatomyositis  
A. Patel; T. M. Pender; M. Rosenkranz
  - P.050 Long-term Outcome of Children with Juvenile Dermatomyositis: a single-centre study from North India  
A. Sharma; A. Gupta; A. Rawat; D. Suri; S. Singh
  - P.051 Presentation Features and Misdiagnosis in anti-MDA5 Autoantibody (Ab) Associated Juvenile Dermatomyositis (JDM)  
G. Mamyrova; L. Wu; A. M. Huber; I. N. Targoff; R. V. Curiel; F. W. Miller; L. G. Rider
  - P.052 Autoantibody Profile of Children with Juvenile Dermatomyositis from a single-centre in North India  
A. Sharma; A. Gupta; A. Rawat; D. Suri; S. Singh
  - P.053 Myositis-specific antibodies in juvenile dermatomyositis and their associated clinical phenotypes in a German cohort  
S. Horn; C. Sengler; N. Grösch; J. Klotsche; J.-P. Haas; C. Hinze; G. Horneff; T. Kallinich; F. Weller-Heinemann; K. Minden
  - P.054 Genetic Differences in the HLA Region Between Adult- and Juvenile-Onset IIM Patients with Anti-TIF1 Autoantibodies  
S. Rothwell; I. E. Lundberg; F. W. Miller; L. G. Rider; L. R. Wedderburn; N. J. McHugh; H. Chinoy; J. Lamb
  - P.055 Using the internationally agreed-upon Consensus Dataset for Juvenile Dermatomyositis (JDM) in clinical practice and research.  
L. McCann; M. W. Beresford; C. A. Pilkington; A. Huber; A. Ravelli; C. T. Deakin; H. Chinoy; L. R. Wedderburn
  - P.056 Physical Function Trajectories in Children with Juvenile Myositis  
K. Ardalan; E. Gray; J. Lee; M. Wolfe; G. Morgan; L. Pachman
  - P.057 Myositis Autoantibodies in Paediatric Idiopathic Inflammatory Myopathies - a Case Series from Singapore  
S. Buvanewarran; P. L. Ooi; P. Chan Ng; K. L. Lee; E. Y. Ang
  - P.058 Myositis damage index in a cohort of children with juvenile dermatomyositis (jDM) from a single centre in Mumbai, India  
S. Godad; P. Pimpale Chavan; R. P. Khubchandani



- P.059 Profile of myositis antibodies in a cohort of children with juvenile dermatomyositis (jDM) from a single centre in Mumbai, India  
Pimpale Chavan; R. Bendre; R. P. Khubchandani
- P.060 Correlation of type I interferon score and interferon induced mediators CXCL10 and neopterin with disease activity in Juvenile Dermatomyositis  
R. Nicolai; I. Caiello; L. Rava; S. Rosina; L. Bracci Laudiero; A. Ravelli; F. De Benedetti; G. M. Moneta
- P.061 Identifying and predicting novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models  
C. T. Deakin; C. Papadopoulou; M. Al-Obaidi; C. A. Pilkington; L. R. Wedderburn; B. L. De Stavola
- P.062 Myositis-Specific Antibodies and Acquired Lipodystrophy in Juvenile Dermatomyositis: Evaluation of Fat Distribution using Dual-Energy X-ray Absorptiometry (DXA)  
A. Khojah; V. Liu; G. Morgan; C.-C. Huang; K. Ardalan; R. Shore; J. Bellm; L. Pachman
- P.063 Investigating Investigating the role of complement activation in driving the Th1/17 imbalance observed in Juvenile Dermatomyositis.  
L. Marshall; E. Rosser; C. Deakin; C. Johnson-Moore; D. Eleftheriou; L. Wedderburn
- Immune-Mediated Necrotizing Myopathies (P.064-P.074)**
- P.064 A single centre experience of immune-mediated necrotising myopathies: a comparison of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase and anti-signal recognition particle Myopathies  
S.-A. Yeoh; R. Thomas; H. Tahir; A. Radunovic
- P.065 Muscular dystrophy masquerading as inflammatory myositis  
C. L. Tan; K. B. Tan; S. Tay; P. L. Ooi; E. Y. Ang
- P.066 Chronic disease course and IVIg-dependance in long-term follow-up of anti-HMGCR Immune-Mediated Necrotizing Myopathies  
O. Landon-Cardinal; K. Mariampillai; C. Anquetil; A. Rigolet; B. Hervier; N. Champtiaux; O. Benveniste; Y. Allenbach
- P.067 Clinical and histological features of necrotising myopathy: a prospective multi-centre Australian cohort study.  
J. Day; S. Otto; K. Cash; V. Limaye
- P.068 Tocilizumab Improve Muscle Strength in Patients with Refractory Anti-Signal Recognition Particle and Anti-3-Hydroxy-3-Methylglutaryl-CoA Reductase Myopathies  
S. Li; W. Li; W. Jiang; L. He; X. Liu; X. Shu; Q. Peng; L. Ma; G. Wang; X. Lu
- P.069 Clinical Characteristics of Immune-Mediated Necrotizing Myopathies: A Retrospective Study in a Single-center Muscle Biopsy Cohort  
H. Yang; X. Tian; H. Yang; Y. Zhang; X. Shu; G. Wang; X. Lu

- P.070 The role of dysfunctional T-cells in immune mediated myositis  
S. Knauss; C. Preuße; Y. Allenbach; S. Leonard-Louis; M. Touat; N. Fischer; H.-R. Radbruch; R. Mothes; V. Matyash; W. Boehmerle; M. Endres; H.-H. Goebel; O. Benveniste; W. Stenzel
- P.071 Use of Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors in statin-associated autoimmune myopathy; a case-series  
E. Tiniakou; A. Mammen; L. Christopher-Stine
- P.072 Clinical presentation and outcome in anti-SRP IMNM: french cohort of 54 patients  
M. Peyre; N. Champtiaux; K. Mariampillai; O. Landon-Cardinal; M. Vautier; B. Hervier; P. Guillaume-Jugnot; A. Rigolet; Y. Allenbach; O. Benveniste
- P.073 Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: Experience from a large single center study  
M. Dastmalchi; S. Barsotti; A. Mammen; K. Pak; K. Gheorghe; I. Lundberg
- P.074 Anti-RNP antibodies delineate a subgroup of necrotizing myositis  
N. Wesner; A. Uruha; S. Suzuki; K. Mariampillai; B. Granger; N. Champtiaux; A. Rigolet; Y. Schoindre; S. Le Jeune; P. Guillaume-Jugnot; M. Vautier; B. Hervier; A. Simon; F. Granier; L. Gallay; I. Nishino; O. Benveniste; Y. Allenbach

16:45 - 20:00 **Team Workshop jDM**

Lecture Hall

Chairs: K Adelan (USA) and L Rider (USA)

1: Medication usage and outcomes in jDM

T Kishi (Japan)

2: Insights from genomic analyses of jDM

C Deakin (UK)

3: Biomarkers of disease activity in jDM: Opportunities for personalised treatment strategies

F v. Wijk (The Netherlands)

4: Vasculopathy in jDM and work in progress

C Gitiaux (France)

5: Selected oral presentations

O.14 The use of metabolomics to develop novel biomarkers for juvenile dermatomyositis

J Dvergsten (USA)

O.15 Endothelial biomarker profiles reflect heterogeneity of juvenile dermatomyositis and may predict disease course

J Wienke (The Netherlands)

O.16 The relationship of pain, fatigue and emotional distress with quality of life in juvenile myositis

K Ardalan (USA)

O.17 Juvenile dermatomyositis – data of a national pediatric rheumatology database

C Sengler (Germany)

16:45 - 18:45 **Speed Funding**

Chairs: Y Allenbach (France), H Chinoy (UK), A Kubota (Japan), A Meyer (France), D Pehl (UK), C Preuße (Germany) and J Tanboon (Japan)

Auditorium II

SPONSORED BY:



Presentation of the six finalists

1. Interferon-mediated impairment of myogenic precursors cells in dermatomyositis  
L Gallay (France)

2. The pathogenesis and treatment of inclusion body myositis in a xenograft model  
K Britson (USA)

3. Mechanisms underlying the therapeutic and iatrogenic response to glucocorticoids in skeletal muscle during inflammatory myopathies  
M Giannini (France)

4. Inclusion body myositis on a chip  
S Lassche (The Netherlands)

5. CD27-CXCR4hiCD21lo cells in Jo1-positive IIM  
E Wilfong (USA)

6. Heart involvement and autoantibody profile in myositis  
S Korsholm (Denmark)

Horizontal lines for taking notes.





---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---


---

---

A microscopic image of skeletal muscle tissue, stained with hematoxylin and eosin (H&E). The image shows numerous muscle fibers with prominent nuclei and a central tendon. The text "FRIDAY" is overlaid in white, bold, sans-serif font. Below it, the date "29 MARCH 2019" is also overlaid in white, sans-serif font. The background is a dense field of pink muscle fibers with scattered blue nuclei.

**FRIDAY**

29 MARCH 2019



**FRIDAY, 29 MARCH 2019**

- 08:30 - 10:00 **Iva Juvenile Dermatomyositis (jDM)** Lecture Hall  
Chairs: A Selva O' Callagan (Spain) and B Bader-Meunier (France)
- 08:30 - 08:55 1: Human type I interferonopathies  
Y Crow (France)
- 08:55 - 09:20 2: The vasculopathy in jDM  
D Eleftheriou (UK)
- 09:20 - 10:00 3: Selected oral presentations
- O.18 Mitochondrial dysfunction: A novel treatment focus  
in juvenile dermatomyositis  
M Wilkinson (UK)
- O.19 Differential peripheral IFN score expression in juvenile  
dermatomyositis vs. Mendelian interferonopathies  
H Kim (USA)
- O.20 Juvenile inflammatory myopathy with anti-MDA5  
auto-antibodies: A specific subgroup demonstrating  
differentially enhanced upregulation of interferon-alpha  
signaling  
I Melki (France)



10:00 - 11:15 **COFFEE BREAK and Exhibition**

Foyer I and II

**Poster Session III (P.075-P.114)**

Colonnade and Foyer I

**Miscellaneous (P.075-P.114)**

- P.075 Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity  
I. Pinal-Fernandez; D. R. Amici; C. Parks; A. Derfoul; M. Casal Dominguez; K. Pak; R. Yeker; P. Plotz; J. C. Milisenda; J. M. Grau-Junyent; A. Selva-O'Callaghan; J. Paik; J. Albayda; A. Corse; T. Lloyd; L. Christopher-Stine; A. Mammen
- P.076 Aberrant expression of 'High Mobility Group Box Protein 1' (HMGB1) in the idiopathic inflammatory myopathies  
J. Day; S. Otto; K. Cash; P. Eldi; S. Proudman; P. Hissaria; J. Hayball; V. Limaye
- P.077 Identification of heat shock factor 1 (HSF1) as a novel autoantigen in idiopathic inflammatory myopathy  
Y. Zhang; Q.-L. Peng; H.-B. Yang; J.-L. Shi; H. Chen; X. Lu; G. Wang
- P.078 Investigating the Specificity of the Myositis Profile-4 EUROLINE assay  
C. Ventin-Rodriguez; J. B. Lilleker; S. Elkhalfifa; H. Chinoy
- P.079 MicroRNA and mRNA profiling in the idiopathic inflammatory myopathies  
J. E. Parkes; A. Thoma; A. Lightfoot; P. J. Day; H. Chinoy; J. A. Lamb
- P.080 Alterations in activin A-myostatin-follistatin system associate with disease activity in inflammatory myopathies  
L. Vernerová; V. Horváthová; T. Kropáčková; M. Vokurková; M. Klein; M. Tomčík; S. Oreská; H. Štorkánová; H. Mann; O. Kryštůfková; J. Vencovský
- P.081 Differential immune response of skeletal muscle groups in idiopathic inflammatory myopathies  
A. Michels
- P.082 Work disability in patients with idiopathic inflammatory myopathies in moldovan myositis group  
N. Loghin-Oprea; S. Vetrila; L. Mazur-Nicorici; V. Salaru; M. Mazur
- P.083 Investigating the Sensitivity and Specificity of the Myositis Profile-4 EUROLINE assay  
C. Ventín-Rodríguez; J. Lilleker; S. Elkhalfifa; H. Chinoy
- P.084 A longitudinal analysis of anti-FHL1 antibodies in a Swedish cohort of patients with Idiopathic Inflammatory Myopathies  
A. S. Galindo-Feria; E. Divišová; C. Fernandes-Cerqueira; M. Dastmalchi; E. Wigren; S. Gräslund; I. E. Lundberg
- P.085 Shear Wave Elastography; Preliminary Validation and Diagnostic Utility in the Evaluation of Muscle  
S. Paramalingam; H. Keen; M. Needham
- P.086 Comparing muscle ultrasound to whole body muscle magnetic resonance imaging to as biomarker of disease activity in patients with new-onset myositis: a prospective cohort study  
J. Lim; F. Smithuis; E. Brusse; J. Hoogendijk; C. Saris; M. Wolvers; R. De Haan; E. Aronica; M. Maas; M. De Visser; F. Eftimov; C. Verhamme; A. van der Kooi



- P.087 May the muscular MRI identify a pattern of muscular involvement in patients with idiopathic inflammatory myopathies? Analysis of a monocentric cohort  
S. Barsotti; M. Barbara; A. Tripoli; G. Aringhieri; C. Cardelli; E. Cioffi; V. Zampa; D. Caramella; M. Mosca; R. Neri
- P.088 Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: a qualitative research study  
P. Chérin; T. Pindi; P. Clerson; A. Dokhan; Y. Fardini; M. Duracinsky; J.-C. Crave; O. Chassany
- P.089 Muscle Function and Health-Related Quality of Life in Patients with Polymyositis and Dermatomyositis  
K. Andreasson; L. Alemo Munters; H. Alexanderson
- P.090 Living with idiopathic inflammatory myopathies – patients' thoughts, fears, and expectations.  
H. Engberg; H. Alexandersson; M. Holmqvist
- P.091 Persons with polymyositis and dermatomyositis experience reduced work ability and quality of life  
M. Regardt; K. Åström
- P.092 Female Sexual Function Impairment in Idiopathic Inflammatory Myopathies  
B. Heřmánková; M. Spiritovic; S. Oreska; H. Storkanova; K. Pavelka; L. Senolt; H. Mann; J. Vencovsky; M. Tomcik
- P.093 Experience of pain in polymyositis and dermatomyositis – a qualitative study  
H. Alexanderson; M. Tasarrofi; M. Regardt
- P.094 A novel autoantibody against DNA damage binding protein-1 in idiopathic inflammatory myopathy  
Y. Hosono
- P.095 Evaluation of the effect of neutralizing anti-IFN- $\alpha$  antibodies produced in one SLE patient vaccinated with IFN-K on myotubes atrophy induced by type I interferon  
A. Mahoudeau; L. Ladislau; Y. Allenbach; T. Croughs; A. Gati; C. Anquetil; D. Amelin; O. Benveniste
- P.096 Patients with inflammatory myopathies admitted in intensive care unit are characterised by recent onset and untreated active disease as well as older age and high comorbidities  
B. Michard; T. Artzner; F. Severac; J. Pottecher; J. Sibilia; B. Geny; A. Meyer
- P.097 Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies  
F. Espinosa-Ortega; M. Holmqvist; H. Alexanderson; H. Storfors; T. Mimori; I. Lundberg; J. Rönnelid
- P.098 Situ Lymphocyte and Dendritic Cell Characterization in Idiopathic Inflammatory Myopathies  
I. Bauer Ventura; D. Reilly; P. Pytel; V. Liarski
- P.099 Performance of the new EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies (IIM) in a Large Monocentric IIM Cohort  
S. Barsotti; V. Leclaire; A. Notarnicola; L. Ekholm; L. Dani; M. Dastmalchi; I. E. Lundberg
- P.100 Tfh Cells in Human Myositis  
A. Puranik; M. Jensen; Y. Ghodke-Puranik; R. Tipon; C. Loomis; V. Mezzano; S. Selvaraj; T. Wampler Muskardin; L. Pachman; A. Reed; T. Niewold



- P.101 Role of mitochondria in membrane repair and muscle weakness in myositis  
K. Nagaraju; J. Boehler; A. Horn; J. Novak; N. Li; S. Ghimbovschi; I. Lundberg; H. Alexanderson; L. Alemo-Munters; J. Jaiswal
- P.102 Features of repeated muscle biopsies and of phenotypes of monocytes in paired blood samples and clinical long-term response to treatment in patients with idiopathic inflammatory myopathy – a pilot study  
K. R. Gheorghe; Q. Tang; X.-M. Zhang; E. Lindroos; H. Alexanderson; C. Wick; M. Bruton; R. A. Harris; I. Nennesmo; I. E. Lundberg
- P.103 The Göttingen Interdisciplinary Immunological Case Conference (GIICC): multi-disciplinary collaboration for effective care pathways of patients with myositis  
P. Korsten; J.-G. Rademacher; C. Seitz; J. Zschüntzsch; R. Mößner; M. Zeisberg; U. Olgemöller; C. Buck; S. Zechel; R. Vasko; J. Schmidt
- P.104 ACR/EULAR myositis classification 2017: “real world data” from the Göttingen cohort  
K. Hasanov; S. Zechel; R. Zeng; S. Glaubitz; P. Korsten; C. S. Seitz; J. Schmidt
- P.105 Incidence of Idiopathic Inflammatory Myopathies (IIM) in Adults in Fife, Scotland, UK  
J. McLaren; P. Allcoat; M. Hearst; E. Furrrie; S. Hailwood
- P.106 Muscle inflammation and muscle weakness in mouse models of neuromuscular diseases  
A. Mullen; J. Rowsell; K. Uaesoontrachoon; A. MacKinnon; M. Praest; S. Srinivassane; W. Ross; D. Shala; J. Warford; E. Hoffman; K. Nagaraju
- P.107 National trends in Utilization of Emergency Department Services and Health Care Cost associated with Idiopathic Inflammatory Myopathy visits: An analysis of Nationwide Emergency Department Survey in United States, 2010-2014.  
U. Zahid; S. Upreti; K. Ellingson; L. Christopher-Stine
- P.108 The prevalence of p62 immunostaining in muscle biopsies from patients with myositis, non-inflammatory myopathies, and neurogenic disorders  
J. C. Milisenda; I. Pinal-Fernandez; T. E. Lloyd; J. M. Grau; A. L. Corse; A. L. Mammen
- P.109 The spectrum of idiopathic inflammatory myopathy in a multi-ethnic Malaysian population  
K. J. Goh; T. Ambang; C. Y. Tan; J. Raja; K. T. Wong
- P.110 The role of Muscle Biopsy Score in Assessing Disease Activity in Adult Patients with Idiopathic Inflammatory Myopathies  
L. Zhang; X. Lu; X. Tian; X. Zheng
- P.111 Hsp90 is increased in plasma and muscle tissue in idiopathic inflammatory myopathies and correlates with disease activity and skeletal muscle involvement  
H. Storkanova; S. Oreska; M. Spiritovic; B. Hermankova; O. Krystufkova; H. Mann; K. Pavelka; J. Vencovsky; L. Senolt; M. Tomcik
- P.112 A high prevalence of conformational epitopes in patients with anti-TIF1 $\gamma$  limits the utility of solid-phase immunoassays as a detection method  
S. Tansley; Z. Betteridge; H. Chinoy; L. Wedderburn; N. McHugh

<p>■ P.113 Towards disentangling the genetics of myositis: the DISSECT project experience  <u>M. Bianchi</u>; A. Notarnicola; T. Dissect Consortium;  L. Pyndt Diederichsen; Ø. Molberg; H. Chinoy; J. Lamb;  L. Rönnblom; K. Lindblad-Toh; I. E. Lundberg</p>	12:30 - 14:00 <b>LUNCH / Genzyme Industry Symposium</b>	Lecture Hall
<p>■ P.114 Predictive factors for treatment response for patients with idiopathic inflammatory myopathies A registry-based cohort.  <u>H. F. Espinosa-Ortega</u>; M. Holmqvist; M. Dastmalchi;  I. E. Lundberg; H. Alexanderson</p>	14:00 - 15:30 <b>V Immune-Mediated Necrotizing Myopathies (IMNM)</b> Chairs: I Lundberg (Sweden) and G Wang (China)	Lecture Hall
<p>11:15 - 12:30 <b>IVb Dermatomyositis (DM)</b>  Chairs: M Fujimoto (Japan) and V Werth (USA)</p>	14:00 - 14:25 1: Macrophages - multidimensional players in inflammatory diseases J Schultze (Germany)	Lecture Hall
<p>11:15 - 11:40 1: Ways to differentiate DM subtypes  W Stenzel (Germany)</p>	14:25 - 14:50 2: Auto-antibodies at the center of IMNM pathogenesis O Boyer (France)	
<p>11:40 - 12:30 2: Selected oral presentations</p> <p>O.21 Identification of six dermatomyositis subgroups using principal component analysis-based cluster analysis  H Zhu (China)</p> <p>O.22 Overexpression of type 1 IFN in skeletal muscle affects muscle function  M Morales (USA)</p> <p>O.23 The role of low-density granulocytes (LDGs) and neutrophil extracellular traps (NETs) in the clinical profile of patients with idiopathic inflammatory myopathies  J Torres-Ruiz (Mexico)</p> <p>O.24 Auto-antibodies targeting components of sarcolemma membrane repair: A pathogenic mechanism in inflammatory myopathies  W Jarjour (USA)</p>	<p>14:50 - 15:30 3: Selected oral presentations</p> <p>O.25 Investigating chaperone-mediated selective autophagy in immune-mediated necrotizing myopathies  N Fischer (Germany)</p> <p>O.26 Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI  O Landon-Cardinal (Canada)</p> <p>O.27 Role of MircoRNAs in immune-mediated necrotizing myopathies through regulation of myogenic differentiation-associated genes  Y Zuo (China)</p>	



15:30 - 16:30 **SNACK BREAK and Exhibition**

Foyer I and II

**Poster Session IV (P.115-P.151)**

Colonnade and Foyer I

**Sporadic Inclusion Body Myositis (P.115-P.131)**

- P.115 Muscle ultrasound in patients with Inclusion Body Myositis: differentiating from mimics  
K. Leeuwenberg; L. Christopher-Stine; J. Paik; E. Tiniakou; N. van Alfen; J. Doorduyn; C. Saris; J. Albayda
- P.116 Quantitative Strength Profiling in Inclusion Body Myositis: Faster Deterioration in Males and Positive Associations with Functional Assessment Tools  
J. Lilleker; A. Oldroyd; H. Chinoy; J. Miller
- P.117 Application of electrical impedance myography (EIM) as a potential biomarker of Inclusion Body Myositis (IBM): A pilot study  
B. Roy; S. B. Rutkove; R. J. Nowak
- P.118 Clinical description of familial inclusion body myositis and molecular genetic analysis  
A. Kubota; H. Ishiura; J. Mitsui; J. Shimizu; S. Tsuji; T. Toda
- P.119 DMF diminishes inflammatory response in muscle cells  
K. Schmidt; A. Faust; S. Kaur; P. Balcarek; J. Schmidt
- P.120 Nonspecific pattern of muscular cN-1A expression in inclusion body myositis  
A. Rietveld; T. Oosterhof; S. Lassche; B. van Engelen; B. Küsters; C. Saris; G. Pruijn
- P.121 The German patient registry for inclusion body myositis  
S. Krause; S. Thiele; M. Heidemann; K. Schmidt; M. Vorgerd; J. Schmidt; M. C. Walter
- P.122 Inclusion Body Myositis (IBM) Symptom Flares and Associated Impact from the Patient Perspective  
A. Kontekakis; W. Nelson; L. Christopher-Stine; W. Kelly; L. Kobert; B. Opong-Owusu; M. Reed
- P.123 Characterization of inflammation-induced mitochondrial cell stress in human skeletal muscle in vitro and ex vivo  
S. Meyer; L. Scholle; S. Zechel; S. Kummer; J. Dudek; H. Lorenz; A. Hell; C. Stadelmann; S. Zierz; J. Zschüntzsch; J. Schmidt
- P.124 Fingolimod and IgG in experimental treatment of an IBM mouse model for muscle regeneration  
P.-O. Carstens; S. Höller; A. Grimm; J. Schmidt
- P.125 Clinical mimics of inclusion body myositis and how to recognize them  
S. Glaubitz; R. Zeng; K. Schmidt; P.-O. Carstens; M. Smogavec; J. Schmidt; J. Zschüntzsch
- P.126 Clinical profile of inclusion body myositis/myopathy (IBM) in a referral neuromuscular center  
P. Soltanzadeh; N. Thakore; R. Prayson; K. Levin
- P.127 Characterising the immune response associated with Inclusion Body Myositis.  
J. Coudert; K. Beer; P. Lamont; M. Needham
- P.128 Association of HLA with anti-cN1A antibodies in IBM patients  
J. Coudert; K. Beer; C. Bundell; A. Bruschi; A. Chopra; M. Needham
- P.129 Reliability and validity of an activity limitation measure in persons with IBM  
M. Regardt; L. Christopher Stine



■ P.130 B cell mechanisms in chronic muscle inflammation  
P.-O. Carstens; L. Müller; A. Wrede; M. Wachowski;  
 A. Brandis; S. Krause; S. Zierz; J. Schmidt

■ P.131 Active immunization mice model of sporadic inclusion body  
 myositis  
N. Tawara

#### Other Forms of Myositis (P.132-P.151)

■ P.132 Unravelling the pathogenesis of brachio-cervical myopathy  
 associated to Scleroderma  
X. Suárez-Calvet; E. Gallardo; J. Alonso-Pérez; I. Castellví;  
 A. Carrasco-Rozas; A. Alonso-Jimenez; S. López-Fernández;  
 J. Turón-Sans; R. Rojas-García; J. Díaz-Manera

■ P.133 Vacuolar myopathy with monoclonal gammopathy and  
 stiffness: A new Monoclonal gammopathy of muscle  
 significance  
Y. Allenbach; E. Salort-Campana; E. Malfatti; B. Eymard;  
 S. Attarian; A. Maues de Paula; A. Rigolet; S. Leonard-Louis;  
 O. Benveniste; T. Stojkovic

■ P.134 Characteristics of myositis - rheumatoid arthritis overlap  
 patients in a Hungarian cohort  
L. Bodoki; Z. Griger; M. Nagy-Vincze; Z. Betteridge; K. Dankó

■ P.135 The Role of Muscle Biopsy Score in the Prediction of the  
 Outcome of Adult Idiopathic Inflammatory Myopathies  
X. Lu; X. Zheng; L. Zhang; X. Tian; Q. Liu; W. Li; Q. Peng;  
 G. Wang

■ P.136 Creatine Kinase in Systemic Sclerosis  
A. Chepy; S. Morell-Dubois; T. Quémeneur; E. Hachulla;  
 N. Le Gouellec

■ P.137 PD-1 and PD-L1 inhibitors-associated myositis, Characteristic  
 histopathological muscle pattern  
A. Matas; A. Selva O'Callaghan; M. N. Antonioli;  
 S. Prieto-González; C. Cabrera; N. Reguart; G. Vila Pijoan;  
 J. M. Grau; J. C. Milisenda

■ P.138 Immune checkpoint inhibitor-associated myositis: a new and  
 severe entity amongst immune inflammatory myopathies  
C. Anquetil; J.-E. Salem; B. Lebrun-Vignes; D. B. Johnson;  
 A. L. Mammen; W. Stenzel; S. Leonard-Louis; O. Benveniste;  
 J. J. Moslehi; Y. Allenbach

■ P.139 Mass cytometry reveals an impairment of B cell homeostasis  
 in Anti-synthetase syndrome  
G. Dzangué-Tchoupou; Y. Allenbach; C. Preusse; W. Stenzel;  
 O. Benveniste

■ P.140 Anti-Jo1 positive myositis patients display a characteristic  
 IgG Fc-glycan profile which is further enhanced in anti-Jo1  
 autoantibodies  
 C. Fernandes-Cerqueira; N. Renard; A. Notarnicola;  
E. Wigren; S. Gräslund; R. Zubarev; I. E. Lundberg; S. Lundström

■ P.141 Association of anti-Ro52 autoantibodies with interstitial  
 lung disease and more severe disease manifestations in  
 juvenile idiopathic inflammatory myopathies  
S. Sabbagh; I. Pinal-Fernandez; T. Kishi; I. Targoff; F. Miller;  
 A. Mammen; L. Rider

■ P.142 Anti-Jo-1 antibody-positive patients show different clinical  
 symptoms, histological features and molecular gene  
 expression compared to anti-PL-7 and anti-PL-12 antibody-  
 positive patients  
B. Paesler; L. Galla; Y. Allenbach; O. Benveniste;  
 N. Streichenberger; W. Stenzel; C. Preuß

- P.143 Hand Radiographic Lesions Are Frequent in Antisynthetase Syndrome Arthritis and Are Associated with a Longer Duration of the Disease  
C. Guillochon-Petitcuenot; G. Balazuc; T. Willaume; G. Bierry; F. Maurier; N. Afif; L. Messer; J.-E. Gottenberg; J. Sibilia; A. Meyer
- P.144 A rare case of anti-PL12 syndrome and Amyotrophic Lateral Sclerosis  
E. Shamim; L. Yarngo; A. Rapp; C. Chan; M. Sinkiewicz; M. Kong; I. Lim
- P.145 Diagnostic value of perifascicular HLA-DR expression in anti-synthetase syndrome associated myopathy  
J. Tanboon; M. Inoue; I. Nishino
- P.146 Interstitial lung disease in Idiopathic Inflammatory Myopathies: ultrasound assessment of pleural irregularities and comparison with clinical, serological and functional aspects  
E. Cioffi; S. Barsotti; C. Romei; A. Tripoli; C. Roncella; C. Cardelli; M. Mosca; F. Falaschi; R. Neri
- P.147 A case of myositis with positive anti-PM/Scl antibody  
S. Biliciler; A. R. Shoraka
- P.148 Anti-tRNA Synthetase and PmScl antibody status is associated with distinct immunophenotypes irrespective of clinical classification  
E. Wilfong; K. Vowell; L. Crofford; P. Kendall
- P.149 Autoantigen Histidyl-tRNA Synthetase (HisRS) is secreted into circulation and inversely correlates with anti-HisRS autoantibody levels  
C. Fernandes-Cerqueira; R. Adams; A. Notarnicola; A. Cubitt; D. J. King; I. E. Lundberg; P.-J. Jakobsson; L. A. Nangle
- P.150 Course of interstitial lung disease in antisynthetase syndrome with immunosuppressive therapy  
L. Riedel; J. Schmidt; J.-G. Rademacher; R. Vasko; P. Korsten
- P.151 Association between pathological features of skeletal muscle and clinical phenotypes in anti-synthetase syndrome  
X. Tian; L. Zhang; H. Yang; Y. Zhang; W. Li; Q. Liu; Q. Peng; X. Lu
- P.152 The experience of Juvenile Dermatomyositis described through poetry  
P. Livermore; L. R. Wedderburn; F. Gibson
- 16:30 - 17:00 **IMACS Meeting** Lecture Hall  
F Miller (USA) and L Rider (USA)
- 17:00 - 17:30 **Establishing a World Myositis Society:** Lecture Hall  
Where do we go from here?  
J Schmidt (Germany)
- 18:30 **Scientific Get-Together** solar SKY-BAR  
SPONSORED BY:  


# Edasalonexent, a Novel NF-κB Inhibitor in Phase 3 Development for the Treatment of Duchenne

Edasalonexent inhibits NF-κB, which is a key link between loss of dystrophin and disease pathology and plays a fundamental role in the initiation and progression of skeletal muscle, bone and cardiac disease in DMD.

Edasalonexent is currently in Phase 3 clinical development for Duchenne muscular dystrophy in our PolarisDMD trial. Learn more at [www.catabasis.com](http://www.catabasis.com)

### Activated NF-κB in DMD

#### Skeletal Muscle

Loss of ambulation, upper limb function, respiratory failure

#### Heart


Cardiomyopathy

#### Bone

Fractures

### Vision for edasalonexent

- ✓ **Improve** skeletal muscle function
- ✓ **Improve** cardiac function
- ✓ **Reduce** risk of fractures



## MYOSITIS UK ARE PLEASED TO BE SPONSORS OF THE 1ST SPEED FUNDING EVENT AT GCOM

We are delighted to support young, talented doctors and scientific researchers investigating Myositis.

Myositis UK provides information to patients and raises funds to support research into Myositis.



146 Newtown Road, Woolston, Southampton, SO19 9HR, UK  
t 023 8044 9708 e [office@myositis.org.uk](mailto:office@myositis.org.uk) [www.myositis.org.uk](http://www.myositis.org.uk)  
Reg Charity No. 327791



---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---




---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---




---

A detailed microscopic image of muscle tissue, showing numerous muscle fibers with visible nuclei and striations. The fibers are arranged in a somewhat regular pattern, with some darker spots and a few small red spots scattered throughout. The overall color palette is warm, ranging from light beige to deep brown and black.

# SATURDAY

30 MARCH 2019





## SATURDAY, 30 MARCH 2019

08:30 - 09:20 **VI New Treatment Options** Lecture Hall

Chairs: S Greenberg (USA) and U Schneider (Germany)

08:30 - 08:55 1: How treatment of haematological malignancies paves the way for future treatment strategies for auto-immune and inflammatory diseases  
O Hermine (France)

08:55 - 09:20 2: Next generation weapons for myositis: Biological or not?  
R Aggarwal (USA)

09:20 - 10:00 **VII Miscellaneous** Lecture Hall

Chairs: Boyer (France) and J Lamb (UK)

Selected oral presentations

O.28 The interferon gene signature in dermatomyositis, the anti-synthetase syndrome, immune-mediated necrotizing myopathies, and inclusion body myositis: A comparative study  
I Pinal-Fernandez (USA)

O.29 Evaluation of a novel particle-based assay for detection of myositis specific antibodies  
K Malyavantham (USA)

O.30 Optimization of muscle NMR imaged segmentation to best discriminate disease progression in adult patients with inflammatory myopathies  
H Reyngoudt (France)

10:00 - 10:30 **COFFEE BREAK and Exhibition** Foyer I and II





10:30 - 11:15	<b>VIII Hot Topics</b> Chairs: HH Goebel (Germany) and J Vencovský (Czech Republic)	Lecture Hall
	Selected oral presentations	
	O.31 Identification of novel auto-antibodies for idiopathic inflammatory myopathies using human proteome microarray L Li (China)	
	O.32 IFN level assessed by ultrasensitive detection technology in myositis patients: A promising biomarker of disease activity in dermatomyositis and anti-synthetase syndrome L Bolko (France)	
	O.33 Analysis of muscle transcriptomic features in idiopathic inflammatory myopathies H Chen (China)	
11:15 - 12:15	<b>IX Patients: Reports from patient association(s)</b> Chair: M Dimachkie (USA)	Lecture Hall
12:15 - 13:15	<b>Prizes</b> T Lloyd (USA) and V Werth (Australia)	Lecture Hall
	<b>General Discussion, Closing and Handover</b> Chairs: O Benveniste (France), I Nishino (Japan) and W Stenzel (Germany)	
13:15 - 14:30	<b>LUNCH</b>	Foyer I and II

---



---



---



---



---



---



---



---



---



---



---



---



---




---



---



---



---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---


---

---

---

---

---




---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



Horizontal lines for writing notes.

Copyrights

Front cover: fotolia.de, ESMT

Front cover inside: Map and Route GmbH & Co. KG

p. 13-15 iStock

p. 16 iStock, Berliner Unterwelten

# Re:member

Professional Congress Organiser

Remember Management GmbH

Albrechtstraße 14 b

10117 Berlin

Tel.: +49 30 47372577

E-mail: [info@remember-management.de](mailto:info@remember-management.de)

[www.remember-management.de](http://www.remember-management.de)

THANK YOU TO ALL SPONSORS AND SUPPORTERS  
OF GCOM 2019

GOLD  
SPONSOR:



SILVER  
SPONSORS:



BRONZE  
SPONSORS:



CONFERENCE  
SUPPORTERS:

